
Blood Glucose Monitoring Devices Market
The Blood Glucose Monitoring Devices Market is expected to reach $21.71 billion by 2032 at a CAGR of 7.5% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 180
- Format
- PDF + Excel
- Report ID
- MRHC - 104786
- Base year
- 2024
- 2032 · FORECAST
- $21.71B
- 2032
- $21.71B
- CAGR 2025–2032
- 7.5%
2024 baseline · 2025–2032 forecast at 7.5% CAGR · hover a bar for the value
Key highlights
In 2025, the Self-monitoring Devices Segment is Expected to Dominate the Blood Glucose Monitoring Devices Market
In 2025, the Type-2 Diabetes Segment is Expected to Dominate the Blood Glucose Monitoring Devices Market
In 2025, the Self/Home Care Segment is Expected to Dominate the Blood Glucose Monitoring Devices Market
In 2025, Asia-Pacific: The Fastest-growing Regional Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 21.71 billion |
| CAGR (2025–2032) | 7.5% |
| Format | PDF, Excel & Cloud Portal · 180 pages |
| Segments Covered | By Product: Self-monitoring Devices Blood Glucose Meters, Test Strips, Lancets, Sensors, Transmitters & Receivers · By Diabetes Type: Type-2 Diabetes, Type-1 Diabetes, Gestational Diabetes · By End User: Self/Home Care, Hospital & Clinics, Other End Users |
| Countries Covered | Europe (RoE), Asia-Pacific (RoAPAC), Latin America (RoLATAM) |
| Key Companies | Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), DexCom, Inc. (U.S.), F. Hoffmann-La Roche Ltd., Medtronic plc, Ypsomed Holding AG, B. Braun Melsungen AG, Nipro Corporation, ARKRAY, Inc. (U.S.), Prodigy Diabetes Care, LLC (U.S.), ACON Laboratories, Inc. (U.S.), Nova Biomedical Corporation (U.S.) |
Report overview
Segments covered: product, diabetes type, end user. Regions: Europe, Asia-Pacific, Latin America.
Blood glucose monitoring devices are used for managing diabetes and monitoring the blood glucose levels of diabetic patients. These devices allow patients to monitor their blood glucose levels in a convenient and minimally invasive manner. The devices perform a quantitative test and provide data on the amount of glucose present in the blood. It helps the patients to manage the disease by monitoring their blood glucose levels and getting medical help when needed.
The growth of this market is driven by the rising prevalence of diabetes, the increasing number of people living unhealthy & sedentary lifestyles, and product innovations in diabetes care. In addition, the growing demand for non-invasive glucose monitoring devices and increasing awareness regarding diabetic health in developing countries are expected to provide significant growth opportunities for this market.
However, the insurance coverage and reimbursement scenarios and product recalls are expected to hinder the growth of this market. In addition, factors such as the large number of people living with undiagnosed diabetes and the high costs of continuous glucose monitoring devices are major challenges to the market’s growth.
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or cannot effectively use it effectively to regulate body sugar. According to the International Diabetes Federation, in 2021, the global prevalence of diabetes was estimated to be 537 million, and it is projected to increase to 643 million by 2032 and 783 million by 2045. The significant growth in the diabetic population is primarily attributed to the increasing number of people living sedentary lifestyles with poor diets and lowered physical inactivity. Diabetes prevalence has risen more rapidly in low- and middle-income countries than in high-income countries. These factors are expected to boost the demand for blood glucose monitoring devices in the coming years.
Continuous glucose monitoring (CGM) devices measure glucose levels automatically and store the readings in a monitor. Generally, continuous blood glucose monitoring devices consist of a sensor worn on the body and automatically obtain frequent glucose readings. The data are manually scanned or wirelessly transmitted to a nearby receiver to display the readings. Patients and their physicians can assess patterns in glucose fluctuations, which helps them make informed decisions about nutrition, physical activity, and medication.
In recent years, the continuous glucose monitoring segment has witnessed significant growth due to the increasing adoption of these devices. In addition, the rapid advancements in technology and design have also enabled the increased adoption of these devices by patients and healthcare providers. This market is expected to grow further as the devices become easier to use, less intrusive, and less expensive.
Report infographic

Table of contents
11 chapters · 93 sections · 180 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product | Self-monitoring Devices | — |
| By Diabetes Type | Type-2 Diabetes | — |
| By End User | Self/Home Care | — |
By Product
- The self-monitoring devices segment is expected to account for the largest share of the blood glucose monitoring devices market.
- The large market share of this segment is attributed to factors such as the high prevalence of type-2 diabetes, the recurring demand for test strips used in blood glucose monitoring devices, and increased awareness about self-management of diabetes.
By Diabetes Type
- The type-2 diabetes segment is expected to account for the largest share of the blood glucose monitoring devices market.
- The large market share of this segment is attributed to factors such as the large population of people with type-2 diabetes, the increasing number of people living unhealthy lifestyles without any physical activity, and the high prevalence of obesity.
By End User
- The self/home care segment is expected to account for the largest share of the blood glucose monitoring devices market.
- The large market share of this segment is attributed to factors such as the increased awareness about self-management of diabetes, the high prevalence of diabetes globally, and the cost-effectiveness offered by blood glucose monitoring devices.
Geographic analysis
Asia-Pacific
Fastest growthAsia-Pacific is slated to register the fastest growth rate in the blood glucose monitoring devices market during the forecast period. The growth of this regional market is driven by the increasing diabetic population, especially in countries such as India and China, government initiatives to increase awareness about self-diabetes management, and the increasing awareness of diabetes management among the population. In 2025, Asia-Pacific: The Fastest-growing Regional Market
Competitive landscape
- Abbott Laboratories (U.S.)
- Becton
- Dickinson and Company (U.S.)
- DexCom, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. · Switzerland
- Medtronic plc · Ireland
- Ypsomed Holding AG · Switzerland
- B. Braun Melsungen AG · Germany
- Nipro Corporation · Japan
- ARKRAY, Inc. (U.S.)
- Prodigy Diabetes Care, LLC (U.S.)
- ACON Laboratories, Inc. (U.S.)
- Nova Biomedical Corporation (U.S.)
Frequently asked questions
This market study covers the market sizes & forecasts of the blood glucose monitoring devices market based on product, diabetes type, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the blood glucose monitoring devices market at the regional and country levels.
Cite this report
Meticulous Research. (2025). Blood Glucose Monitoring Devices Market - Global Opportunity Analysis And Industry Forecast ( 2025-2032) (Report No. MRHC - 104786). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/blood-glucose-monitoring-devices-market-5470